Medical/Pharmaceuticals

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

GAITHERSBURG, Md. and SUZHOU, China, May 30, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the launch of a Phase I clinical trial of the Company's si...

2022-05-30 16:40 2211

Experts attending P&G Health's Global Webinar Series highlight underdiagnosis concerns as Peripheral Neuropathy becomes more prevalent

- Often underestimated and diagnosed late, increasing awareness and early-stage screening of Peripheral Neuropathy by primary care physicians can help prevent long-term complications and quality of life restrictions. - The Global Webinar Series for healthcare professionals has 'Virtual Pavilions...

2022-05-30 16:12 2326

RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

STOCKHOLM, May 30, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today onMay 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (on...

2022-05-30 11:04 1670

United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria

TAIPEI, May 30, 2022 /PRNewswire/ -- Taiwan-based United BioPharma (UBP) has announced the approval of a Phase 2 clinical trial with novel anti-IgE monoclonal antibody UB-221 by the Taiwan Food and Drug Administration (TFDA). 

2022-05-30 10:59 1693

Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.

MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68...

2022-05-30 08:02 2671

MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval, making it the first limus DEB to be available to US patients

GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR was also the first DEB (Drug Eluting Balloon) granted "breakthrough device de...

2022-05-30 08:00 2159

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN DIEGO and SUZHOU, Chi...

2022-05-27 09:30 5009

Menarini inaugurates new regional headquarters in Dubai, UAE

The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across theMiddle East and Africa (MEA) region with innovative products and breakthrough research DUBAI, UAE, May 26, 2022 /PRNewswire/ -- Menarini, the leading Italian pharmaceutical gro...

2022-05-26 23:16 2988

US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD

Key Highlights: * US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company * Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of ne...

2022-05-26 20:44 2221

OLON ANNOUNCES THE CREATION OF A MAJOR CENTER OF RESEARCH AND DEVELOPMENT IN ITALY, THAT WILL GIVE RISE TO AN INNOVATIVE GLOBAL R&D MODEL

MILAN, May 26, 2022 /PRNewswire/ -- Olon, Leading API supplier, announces the creation of an R&D hub at its center inMilan, home to the Group's headquarters, paving the way for further major expansion and diversification of its expertise applied to the development of APIs for the CDMO and Generic...

2022-05-26 19:00 1800

"To China, Empower Your Shared Future" the 2nd Round of CIIE Medtech Roadshow Open for Application Now

SHANGHAI, May 26, 2022 /PRNewswire/ -- "To China, Empower Your Shared Future" the 2nd CIIE Innovation Incubation Area - one of the most distinguished medtech trade show inChina has been officially launched since March, 2022. On the China International Import Expo (CIIE) platform, CIIE Innovation ...

2022-05-26 15:44 2139

DeepGI AI - A Thai Innovation for the Precision in Colorectal Polyp Detection

BANGKOK, May 26, 2022 /PRNewswire/ -- Chula Engineering and Chula Medicine co- invent an innovative device for a rapid gastrointestinal cancer detection that yields accurate results hoping to foster preventive medicine in gastrointestinal malignancy and reduce the number of cancer patients.

2022-05-26 10:10 2464

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...

2022-05-26 08:07 2632

TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE

STOCKHOLM, May 26, 2022 /PRNewswire/ -- A new study with TikoMed's platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of amyotrophic lateral sclerosis (ALS). The st...

2022-05-26 03:40 1967

Golden Meditech Stem Cells Responds to Unfounded Accusations

HONG KONG, May 25, 2022 /PRNewswire/ -- On May 25, 2022, Golden Meditech Stem Cells (BVI) Company Limited (the "Company"), would like to respond to the accusations made against the Company in relation to the Company's enforcement of its rights under the Share Charge Agreement between the Company ...

2022-05-25 23:18 3382

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

HYDERABAD, India and BOSTON, May 25, 2022 /PRNewswire/ -- Excelra, a leading global data and digital insights organization, today announced a partnership with HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for th...

2022-05-25 23:04 2931

The Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBion

HAMILTON, ON, May 25, 2022 /PRNewswire/ -- The Centre for Probe Development and Commercialization (CPDC) is pleased to announce the initiation of a development, manufacturing, and supply agreement withCellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. Under the terms of the agreeme...

2022-05-25 21:00 1361

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 2206

Dr Ivan Puah Expands Service To Sports Aesthetics® To Meet Demands Of Sportspeople

Sports aesthetics® is a term coined by Dr Ivan Puah based on the three pillars of combining unique service offerings to help fitness enthusiasts, sportspeople and professional athletes attain their ideal physiques without compromising the quality of their physical health. SINGAPORE, May 25,...

2022-05-25 16:07 2236

DoctorOnCall Inks MoU with (Pertubuhan Doktor-Doktor Islam Malaysia) PERDIM to Bridge Healthcare Providers and Patients Through Digital Platform

The partnership will propel PERDIM's digital healthcare capabilities and increase revenue by offering an online database of healthcare products, services and treatments across the nation. KUALA LUMPUR, Malaysia, May 25, 2022 /PRNewswire/ -- Malaysia's first and largest digital health platform, H...

2022-05-25 11:08 3033
1 ... 156157158159160161162 ... 386